Infection Control for the Human and Animal Health Market is predicted to reach USD 20.95 billion at a CAGR of 8.16% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Infection Control for the Human and Animal Health Market”.

The global infection control for the human and animal health market is projected to register a CAGR of 8.16% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global infection control for the human and animal health market are Advanced Sterilization Products (US), STERIS plc (Ireland), Getinge AB (Sweden), Virox Technologies, Inc. (Canada), 3M (US), Zoetis Animal Healthcare (US), PeproTech Sciences Inc (Canada), Neogen Corporation (US), Cardinal Health (US), and Stryker (US).

Market Highlights

The global infection control for the human and animal health market is accounted to register a CAGR of 8.16% during the forecast period and is estimated to reach USD 20.95 billion by 2032.

The growing prevalence of infectious diseases, coupled with heightened awareness of infection control measures, stringent regulatory guidelines in healthcare and animal health settings, are anticipated to fuel the adoption of disinfection products. Furthermore, rapid technological advancements, along with a surge in veterinary care and animal health awareness, alongside increasing healthcare expenditure, are expected to contribute significantly to this trend.

Moreover, the increasing prevalence of infectious diseases serves as a significant driver for global infection control for the human and animal health market. In recent years, there has been a notable surge in the prevalence of various infectious diseases worldwide, contributing to an increased demand for infection control products and measures. According to the data published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, approximately 39 million patients were living with HIV across the globe. This increasing burden of infectious diseases amplifies the need for robust infection control practices across healthcare settings, veterinary facilities, and public spaces. As a result, the market for disinfection products, personal protective equipment (PPE), and sterilization equipment is witnessing heightened demand as stakeholders strive to mitigate the impact of infectious diseases. The upward trajectory of infectious disease incidence is expected to sustain the momentum of growth in the infection control market, driving innovation and adoption of advanced solutions to combat the spread of infections effectively.

However, the shortage of skilled healthcare personnel and cost constraints in infection control are anticipated to hamper the market growth. Nonetheless, it is anticipated that the growing demand for technologically advanced and sustainable infection control solution are creating lucrative opportunities for the global infection control for the human and animal health market.

Access full report @ https://www.marketresearchfuture.com/reports/infection-control-for-the-human-animal-health-market-21608

Segment Analysis

The global infection control for the human and animal health market has been segmented based product, infection type, and end user.

On the basis of the product, the global infection control for the human and animal health market is segmented into disinfection products, personal protective equipment (PPE), and sterilization equipment. Disinfection products is divided into liquid disinfectants, disinfectant wipes, disinfectant sprays, and others; personal protective equipment (PPE) is segregated into gloves, masks, gowns, protective eyewear, and others, and sterilization equipment segment is segmented into Heat sterilization equipment, low-temperature sterilization equipment, radiation sterilization equipment, and filtration sterilization equipment. The personal protective equipment (PPE) segment accounted for the largest market with a market share of over 41.26% in 2022 and is anticipated to be the fastest-growing for the forecast period of 2023–2032. This is due to the increasing awareness about the importance of personal safety and hygiene, particularly in healthcare and animal health settings, driven by the ongoing global health challenges and regulatory guidelines emphasizing infection control practices. Amid the ongoing threat posed by infectious diseases, both healthcare professionals and the general populace are increasingly emphasizing the importance of utilizing personal protective equipment (PPE) to mitigate transmission risks. Furthermore, the continuous advancements in PPE technology, coupled with escalating investments in global healthcare infrastructure, are poised to drive an even greater demand for personal protective equipment in the foreseeable future.

Based on infection type, the global infection control for the human and animal health market is segmented into viral, bacterial, parasitic, and fungal infections. The bacterial segment accounted for the largest market in 2022 and is anticipated to be the fastest-growing for the forecast period of 2023–2032. Bacterial infections are prevalent across various healthcare and animal health settings, necessitating robust infection control measures. Additionally, the emergence of antibiotic-resistant bacteria underscores the urgency for effective infection control strategies, further driving the demand for bacterial infection control products.

Based on end user, global infection control for the human and animal health market is segmented into human healthcare facilities and animal healthcare facilities. Human healthcare facilities segment is segmented into hospitals & clinics, ambulatory surgical centers, others and animal healthcare facilities is segregated into veterinary hospitals, animal shelters, farming facilities, and others. The hospitals & clinics segment accounted for the largest share in 2022 and is the fastest-growing segment during the forecast period. Hospitals and clinics are primary sites for diagnosis, treatment, and prevention of infectious diseases in human patients, making stringent infection control measures imperative. Additionally, the increasing prevalence of healthcare-associated infections (HAIs) and the growing awareness of infection control practices among healthcare providers and patients are driving the demand for infection control products and solutions in hospitals and clinics.

Regional Analysis

The global infection control for the human and animal health market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. North America further includes US and Canada. Europe includes countries namely Germany, France, UK, Italy, Spain, and the Rest of Europe. The global infection control for the human and animal health market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.

North America's leading position in terms of revenue share in the infection control market for both human and animal health in 2022 can be attributed to several key factors. The region boasts advanced healthcare infrastructure and facilities, with a strong emphasis on infection prevention and control measures across various healthcare settings. Additionally, the region is at the forefront of technological advancements and innovation in infection control products and solutions, driving adoption rates. Moreover, increasing product launches is expanding the market and market players product portfolios. For instance, in November 2020, Neogen Corporation (US) unveiled COMPANION Foaming Hand Soap. Neogen's new COMPANION Foaming Antibacterial Hand Soap kills 99.9% of harmful bacteria and has a light, fresh scent. It also doesn't dry out the skin when used frequently. The product is packaged in one-gallon refillable containers and 16.9-ounce hand pump-compatible sink-safe containers.

Moreover, Europe shows significant growth during the forecast period due to the rising incidence of zoonotic diseases emphasizes the interconnectedness of human and animal health, fostering a growing market for integrated infection control solutions. As Europe places greater emphasis on public health infrastructure and preparedness, opportunities emerge for companies specializing in diagnostics, personal protective equipment, and vaccination technologies. This evolving landscape requires stakeholders to navigate regulatory frameworks, leverage technological advancements, and capitalize on collaborative initiatives to address the diverse challenges posed by infectious diseases. In 2020, Getinge AB (Sweden) has implemented faster indicators to enhance patient safety. The new Superfast 20 indicators are ISO 11138 compliant and work with most types of steam and hydrogen peroxide sterilizers, as it is critical for any hospital that sterile instruments are delivered to the end user in a safe and timely manner. Finally, the European infection control market is poised for expansion, offering fertile ground for innovation, collaboration, and sustainable growth across both human and animal health domains.

Furthermore, the Asia-Pacific infection control for the human and animal health market is the fastest growing and present lucrative growth opportunities for the global market due to increasing demand for animal products and coupled with a growing awareness of responsible and sustainable farming practices, is leading to investments in preventive measures. Additionally, the rising concern about zoonotic diseases and the need to ensure food safety are prompting the development and adoption of advanced infection control measures in the animal health sector.

Rest of the world regions have witnessed a significant focus on infection control measures for both human and animal health. The demand for effective solutions has been on the rise, driven by factors such as increasing awareness, growing healthcare infrastructure, and the need to combat infectious diseases. According to the World Health Organisation, Africa has seen a 63% increase in diseases transmitted from animals to humans over the last decade. ROW region has been actively investing in infection control strategies to address the challenges posed by communicable diseases. The COVID-19 pandemic has underscored the importance of robust infection prevention and control measures. Governments and healthcare authorities in these regions have prioritized the enhancement of healthcare facilities, the implementation of stringent hygiene protocols, and the adoption of advanced technologies to curb the spread of infections.

Key Findings of the Study

• 
  

  The global infection control for the human and animal health market is expected to reach USD 20.95 billion by 2032, at a CAGR of 8.16% during the forecast period.

  
  


• 
  

  The Europe region held the second largest market share of the global market, owing to increasing surgical procedures and the presence of renowned market players.

  
  


• 
  

  Based on infection type, the bacterial segment held the largest market with a market share of 39.98% in 2022 and is the fastest-growing segment during the forecast period.

  
  


• 
  

  Advanced Sterilization Products (US), STERIS plc (Ireland), Getinge AB (Sweden), Virox Technologies, Inc. (Canada), 3M (US), Zoetis Animal Healthcare (US), PeproTech Sciences Inc (Canada), Neogen Corporation (US), Cardinal Health (US), and Stryker (US) are the key players in the market.